J. Life Sci. Biomed. 6(5): 100-105, September 25, 2016  
JLSB  
Journal of  
ISSN 2251-9939  
Life Science and Biomedicine  
Screening of Novel Angiotensin I Converting Enzyme  
Inhibitory Peptides Derived From Enzymatic  
Hydrolysis of Salmon Protamine  
Fikriyah Rasyad1,2 , Tzou-Chi Huang2, Jue-Liang Hsu2, Mohamad Fadjar1  
¹ Department of Aquaculture, University of Brawiaya, Indonesia  
2 Department of Biological Science and Technology, National Pingtung University of Science and Technology, Taiwan  
Corresponding author's Email: fikriyah.rasyad@gmail.com  
Received 05 Aug. 2016; Accepted 07 Sep. 2016  
ABSTRACT: Angiotensin I converting enzyme (ACE) inhibitory peptide is widely recognized as useful  
therapeutic approach in the treatment of hypertension. Bioactive peptides from natural sources, including  
marine fish, are more considered because it has no harm effects. The objective of this study is screening the  
presence of potential ACE inhibitory peptide from salmon protamine. ACE inhibitory peptide was purified  
from salmon protamine after 16 hours of hydrolysis by various enzymes and centrifuged using 3 kDa  
molecular weight cut off (MWCO) ultrafiltration membrane. The peptide sequences were analyzed by Liquid  
Chromatography Tandem Mass Spectrometric (LC-MS/MS). ACE inhibitory activity was measured using  
Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC). The results indicated that trypsin  
hydrolysate had the highest ACE inhibitory activity compared to the other hydrolysates with IC50 value 135.96  
μg/ml. LC-MS/MS analysis of tryptic protamine identified two major peaks with three peptide sequences, Ser-  
Ser-Arg-Pro-Ile-Arg (SR-6), Ser-Ser-Ser-Arg-Pro-Ile-Arg (SR-7), Pro-Arg-Arg-Ala-Ser-Arg (PR-6) which sourced  
from salmine of Chum Salmon (Oncorhynchus keta). The ACE inhibitory peptides from Salmon Protamine still  
has not been reported previously, therefore it can be beneficial for preventing hypertension.  
Author Keywords: Angiotensin I Converting Enzyme (ACE), Antihypertensive, Bioactive Peptide, Chum  
Salmon (Oncorhynchus keta), Enzymatic hydrolysate, Salmon Protamine  
INTRODUCTION  
Nowadays, the inhibition of ACE activity is commonly known as a functional therapeutic agent for  
preventing and curing hypertension. It has been in use for the last two decades and the tendency to use them will  
be continuously increased [1]. Currently, several synthetic antihypertensive drugs based on ACE inhibitors have  
been clinically used such as captopril, enalapril, alcacepril, and lisinopril [2]. Even though these synthetic ACE  
inhibitors could be possibly utilized as antihypertensive drugs, unfortunately they still have some undesirable  
side effects such as coughing, allergic reactions, taste disturbance, and skin rashes [3]. Thus, developments and  
investigations to explore a beneficial and economical ACE inhibitors are required to prevent hypertension.  
One of the most popular and favorite fish in the world is Salmon. It is considered to be healthy due to its  
high nutritional value and pharmacological activity. Previous studies have investigated ACE inhibitory peptides  
from Salmon by-product such as fillet and residuals [4], skin [5, 6], and pectoral fin [7]. However, the ACE  
inhibitory peptides from Salmon Protamine still has not been reported.  
The objectives of this study were to hydrolysis protein using different proteases, and the protein  
hydrolysate was assessed for bioactivity including angiotensin converting enzyme (ACE) inhibitory activity.  
Furthermore, the sequences of the bioactive peptides were determined by LC-MS/MS [8].  
To cite this paper: Rasyad F, Huang TC, Hsu JL, Fadjar M. 2016. Screening of Novel Angiotensin I Converting Enzyme Inhibitory Peptides Derived From Enzymatic  
Hydrolysis of Salmon Protamine. J. Life Sci. Biomed. 6(5): 100-105; www.jlsb.science-line.com  
100  
MATERIALS AND METHODS  
Salmon Protamine were treated with a single protease, with an enzyme to protein ratio of 1:50 (w/w) using  
different temperatures which were based on the enzymes' activities: trypsin (37 °C), α-chymotrypsin (37 °C),  
pepsin (37 °C), and thermolysin (60 °C). The enzymatic digestions of the salmon protamine were kept at pH 8,  
except for pepsin, which was adjusted to pH 1.3. After incubation for 16 hours, the hydrolysis was stopped by  
centrifugation at low temperature (14,000 rpm, 10 min, 4 °C) in ultrafiltration membrane (3 kDa MWCO). The  
filtrate (<3 kDa) was lyophilized and kept at −20 °C for further assay or analysis.  
The ACE inhibitory activity was determined according to the method reported by Cushman et al [9] with  
partial modification. The sample solution containing 30 μl of 2.5 mM hippuryl-L-histidyl-L-leucine (HHL) as a  
substrate and 10 μl of inhibitor (at an indicated concentration) in 200 mM borate buffer containing 300 mM NaCl  
(adjusted to pH 8.3) was pre-incubated at 37 °C for 5 minutes. The control solution was prepared using the same  
buffer but without inhibitor. Afterwards, 20 μl of 2 mU/ml ACE in 200 mM borate buffer was added to the sample  
solution and control solution, individually. The reaction mixture was incubated statically at 37 °C for 30 minutes  
and then shaken in a thermostatically controlled shaker incubator (200 rpm) at 37 °C for 30 minutes. The  
reaction was quenched under acidic conditions by adding 1 M HCl (60 μl). Ferulic acid 0.2 mg/ml (10 μl) was used  
as an internal standard for normalizing variation derived from different samples. HHL and its hydrolyzed product,  
hippuric acid (HA) were analyzed using an HPLC equipped with a C18 column. The resulting HA was detected  
using a UV detector fixed at 228 nm. The ACE inhibition (%) was determined based on the following equation:  
[1–(ΔAinhibitor/ΔAcontrol) ] x 100  
where ΔAinhibitor was the peak area of HA in the reaction mixture by the presence of peptide as ACE  
inhibitor and ΔAcontrol was the peak area of HA in the reaction mixtures without peptide as ACE inhibitor.  
Definition of ACE activity: One unit (U) of ACE activity was defined as the amount of enzyme required to catalyze  
formation of 1 µmol of HA from HHL per minute at 37 ⁰C.  
The peptide sequences in the lyophilized hydrolysate were further identified using LC-MS/MS analysis and  
database matching. Freeze dried peptides were dissolved in 5% ACN (Acetonitrile) and 0.2% FA (Ferulic acid) in  
deionized water for LCMS/MS analysis. LCMS/MS analysis was performed using a Thermo LCQ DECA XP MAX  
system with an electrospray ionization (ESI) source (Thermo Scientific Inc., USA). Samples were loaded onto a  
BioBasic C18 column with diameter 150 × 2.1 mm, particle size 5 μm. The mobile phase consisted of Solution A  
(100% deionized water and 0.1% FA) and Solution B (100% ACN and 0.1% FA) and was kept at a flow rate of 200  
μl/min. The MS/MS raw data were acquired using Thermo-XCalibur™ Thermo-Scientific) then processed into  
MGF files using Mascot Distiller v2.3.2.0 (Matrix Science, London, UK). The resulting MGF files were searched  
using the Mascot search engine v2.3 (Matrix Science, UK).  
RESULTS AND DISCUSSIONS  
ACE inhibitory activity of each hydrolysates is shown in Figure 1. Captopril is used as positive control. All  
hydrolysates have potential to inhibit ACE, but compared to other hydrolysates, the highest inhibition was shown  
in tryptic hydrolysate with 94.82% followed by chymotrypsin, thermolysin and pepsin with the inhibition of  
79.11%, 70.20%, 48.66% respectively.  
Tryptic hydrolysate, because it has the highest ACE inhibition, further was analyzed for IC50 of ACE  
inhibition activity. The IC50 or the half maximal inhibitory concentration represents the concentration of a peptide  
that is required for 50% inhibition of its target enzyme. To find out the IC50 value of crude hydrolysates, the  
relative ACE inhibition was first determined for various concentrations of peptide; afterwards, the IC50 was  
evaluated by plotting the curves of relative ACE inhibition against six different peptide concentrations (Figure 2).  
The IC50 value of tryptic hydrolysate was considered as a low inhibition. The low IC50 value may be due to  
cumulative and synergistic effects of various active peptides present in each hydrolysate [10].  
To characterize the peptide identities, the lyophilized tryptic hydrolysate was subjected into LC-MS/MS for  
analysis of ACE inhibitory peptides. Two major peaks were observed in the LC-MS chromatogram. Through LC–  
MS/MS analysis and database-assisted identification, peptides derived from Salmon Protamine are compared to  
the predicted peptides forecasted by peptide sequence application. All the sequences are summarized in Table 1.  
LC-MS/MS analysis indicated two major peaks with three peptide sequences. A peptide was located at the  
first peak with retention time at minute 1.74, whereas two other peptides were located at the second peak with  
retention time at minute 10.70 and 10.95 respectively. Based on Mascot Distiller database search, for triply  
To cite this paper: Rasyad F, Huang TC, Hsu JL, Fadjar M. 2016. Screening of Novel Angiotensin I Converting Enzyme Inhibitory Peptides Derived From Enzymatic  
Hydrolysis of Salmon Protamine. J. Life Sci. Biomed. 6(5): 100-105; www.jlsb.science-line.com  
101  
charged the peptide with m/z at 247.91 was identified as Pro-Arg-Arg-Ala-Ser-Arg (PRRASR), for doubly charged  
the peptide with m/z at 358.60 as Ser-Ser-Arg-Pro-Ile-Arg (SSRPIR) and m/z at 402.03 as Ser-Ser-Ser-Arg-Pro-Ile-  
Arg (SSSRPIR).  
Figure 1. ACE inhibitory activities of enzymatic hydrolysates from Salmon Protamine.  
Figure 2. IC50 of tryptic hydrolysate from salmon protamine.  
Table 1. Comparison of tryptic hydrolysate and predicted tryptic peptide sequences.  
Tryptic Hydrolysate Peptides  
Predicted Tryptic Peptides  
m/z  
Position  
6-12  
Sequence  
m/z  
Position  
6-12  
Sequence  
802.0454  
715.1854  
740.9328  
SSSRPIR  
SSRPIR  
PRRASR  
802.4530  
428.2728  
333.1881  
SSSRPIR  
RPR  
7-12  
15-17  
19-21  
16-21  
ASR  
To cite this paper: Rasyad F, Huang TC, Hsu JL, Fadjar M. 2016. Screening of Novel Angiotensin I Converting Enzyme Inhibitory Peptides Derived From Enzymatic  
Hydrolysis of Salmon Protamine. J. Life Sci. Biomed. 6(5): 100-105; www.jlsb.science-line.com  
102  
Figure 3. LC-MS chromatogram of tryptic hydrolysate  
Figure 4. LC-MS chromatogram of peptide SSSRPIR  
To cite this paper: Rasyad F, Huang TC, Hsu JL, Fadjar M. 2016. Screening of Novel Angiotensin I Converting Enzyme Inhibitory Peptides Derived From Enzymatic  
Hydrolysis of Salmon Protamine. J. Life Sci. Biomed. 6(5): 100-105; www.jlsb.science-line.com  
103  
Figure 5. Mass spectrum of peptide with m/z 402.03 for doubly charged and m/z 802.42 for singly charged.  
Recently, salmon protamine widely used for pharmaceutical excipients. This cationic peptide derived from  
salmon milt. Protamine itself has a molecular mass of approximately 4000 Da with about 70% of the basic amino  
acid arginine. Basically, protamines belong to a diverse protein family of arginine rich peptides. Peptides derived  
from protamine could be useful to observe the differential in vitro antimicrobial activity of a 12-residue-long  
arginine-rich peptide and examined against bacterial and parasite microbes. Protamine C-terminal fragment can  
be utilized as a potential new antimicrobial peptide [11].  
In addition to medical and antimicrobial use, Salmon Protamine is also expected could be used as  
antihypertensive agent. Higher level of arginine can be investigated for hypertension therapy. Since the arginine-  
rich peptides also exhibited moderate in vitro ACE and renin inhibitory activities, it is also possible that more than  
one mechanism was involved in producing the antihypertensive effects [12].  
Digestion of salmon protamine by various digestive enzymes has resulted the release of bioactive peptides.  
Chymotrypsin, pepsin, thermolysin and trypsin are some of commonly used and widely distributed commercial  
enzymes. According to the result of this research, tryptic hydrolysate of salmon protamine has the highest ACE  
inhibitory activity. It indicated that bioactive peptides hydrolysis strongly affected by protease. Trypsin is widely  
used to produce ACE inhibitory peptides. However, other proteinases (chymotrypsin, pepsin, thermolysin) as well  
as enzymes from bacterial and fungal sources have been utilized to generate bioactive peptides [13].  
CONCLUSION  
Angiotensin I Converting Enzyme (ACE) Inhibitory peptides were screened from enzymatic hydrolysis of  
salmon protamine using various enzymes. Tryptic hydrolysate has the highest ACE inhibitory activity. LC-MS/MS  
analysis of tryptic protamine identified two major peaks with three peptide sequences, Ser-Ser-Arg-Pro-Ile-Arg  
(SR-6), Ser-Ser-Ser-Arg-Pro-Ile-Arg (SR-7), Pro-Arg-Arg-Ala-Ser-Arg (PR-6) which sourced from salmine AII of  
Chum Salmon (Oncorhynchus keta). According to this study, it can be concluded that bioactive peptide derived  
from salmon protamine has a potential ACE inhibitory peptide. Further study of ACE inhibitory peptide from  
Salmon protamine and the antihypertensive effect on spontaneous hypertensive rat (SHR) is highly needed in  
order to discover a new innovation in the treatment of hypertension.  
Competing interests  
The authors declare that they have no competing interests.  
To cite this paper: Rasyad F, Huang TC, Hsu JL, Fadjar M. 2016. Screening of Novel Angiotensin I Converting Enzyme Inhibitory Peptides Derived From Enzymatic  
Hydrolysis of Salmon Protamine. J. Life Sci. Biomed. 6(5): 100-105; www.jlsb.science-line.com  
104  
REFERENCES  
1. Pfeffer MA and Frohlich ED. 2006. Improvements in clinical outcomes with the use of angiotensin-converting  
enzyme inhibitors: cross-fertilization between clinical and basic investigation. American Journal of  
Physiology, Heart and Circulatory Physiology. 291: H2021-2025.  
2. Wijesekara I and Kim SK. 2010. Angiotensin-I-Converting Enzyme (ACE) Inhibitors from Marine Resources:  
Prospects in the Pharmaceutical Industry. Marine Drugs. 8: 10801093.  
3. Atkinson AB and Robertson JI. 1979. Captopril in the treatment of clinical hypertension and cardiac failure.  
Lancet (London, England). 2: 836839.  
4. Dragnes BT, Stormo SK, Larsen R, Ernstsen HH and Elvevoll EO. 2009. Utilisation of fish industry residuals:  
Screening the taurine concentration and angiotensin converting enzyme inhibition potential in cod and  
salmon. J ournal of Food Composition and Analysis. 22: 714717.  
5. Gu RZ, Li CY, Liu WY, Yi WX and Cai MY. 2011. Angiotensin I-converting enzyme inhibitory activity of low-  
molecular-weight peptides from Atlantic salmon (Salmo salar L.) skin. Food Research International.  
44:15361540.  
6. Lee JK, Jeon JK, Byun HG. 2014. Antihypertensive effect of novel angiotensin I converting enzyme inhibitory  
peptide from chum salmon (Oncorhynchus keta) skin in spontaneously hypertensive rats. Journal of  
Functional Foods. 7: 381389.  
7. Ahn CB, Jeon YJ, Kim YT and Je JY. 2012. Angiotensin I converting enzyme (ACE) inhibitory peptides from  
salmon byproduct protein hydrolysate by Alcalase hydrolysis. Process Biochemistry. 47: 22402245.  
8. Sunantha K and Saroat R. 2013. Purification and characterization of ace inhibitory peptide from aquatic  
resources: Review Sunantha Ketnawa and Saroat Rawdkuen Program of Food Technology , School of Agro-  
Industry, Mae Fah Luang University, To whom correspondence shou. International Journal of Plant, Animal  
and Environmental Sciences. 3: 220233.  
9. Ondetti MA, Rubin B and Cushman DW. 1977. Design of specific inhibitors of angiotensin-converting enzyme:  
new class of orally active antihypertensive agents. Science. 196: 441444.  
10. Salampessy J, Reddy N, Kailasapathy K and Phillips M. 2015. Functional and potential therapeutic ACE-  
inhibitory peptides derived from bromelain hydrolysis of trevally proteins. Journal of Functional Foods.  
4:716725.  
11. Lesmes LP, Bohorquez MY, Carreño LF, Patarroyo ME and Lozano JM. 2009. A C-terminal cationic fragment  
derived from an arginine-rich peptide exhibits in vitro antibacterial and anti-plasmodial activities governed  
by its secondary structure properties. Peptides. 30: 21502160.  
12. Udenigwe CC and Mohan A. 2014. Mechanisms of food protein-derived antihypertensive peptides other than  
ACE inhibition. Journal of Functional Foods. 8:4552.  
13. Ambigaipalan P, Al-Khalifa AS and Shahidi F. 2015. Antioxidant and angiotensin I converting enzyme (ACE)  
inhibitory activities of date seed protein hydrolysates prepared using Alcalase, Flavourzyme and  
Thermolysin. Journal of Functional Foods. 18: 1125-1137  
To cite this paper: Rasyad F, Huang TC, Hsu JL, Fadjar M. 2016. Screening of Novel Angiotensin I Converting Enzyme Inhibitory Peptides Derived From Enzymatic  
Hydrolysis of Salmon Protamine. J. Life Sci. Biomed. 6(5): 100-105; www.jlsb.science-line.com  
105